{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:50:18Z","timestamp":1784069418896,"version":"3.55.0"},"reference-count":19,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>In this update, we discuss the use of real-world data in the Haute Autorit\u00e9 de Sant\u00e9 assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.<\/jats:p>","DOI":"10.57264\/cer-2026-0073","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:13:26Z","timestamp":1776323606000},"source":"Crossref","is-referenced-by-count":1,"title":["R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25"],"prefix":"10.57264","volume":"15","author":[{"given":"Paul","family":"Arora","sequence":"first","affiliation":[{"name":"Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada"},{"name":"Inka Health, 100 King St W. Suite 1600. Toronto, ON M5X 1G5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeram V","family":"Ramagopalan","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0120"},{"issue":"1","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/S0266462325103425","article-title":"Use of RWD in the assessment of economic evaluations of innovative health products: lessons learned from the French National Authority for health (HAS)","volume":"42","author":"Ghabri S","year":"2026","unstructured":"Ghabri S, Sion M. Use of RWD in the assessment of economic evaluations of innovative health products: lessons learned from the French National Authority for health (HAS). Int. J. Technol. Assess. Health Care 42(1), e12 (2026).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2026-0019"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0008"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0033"},{"issue":"1","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41408-025-01420-8","article-title":"Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies","volume":"15","author":"Taylor L","year":"2025","unstructured":"Taylor L, Chen A, Pierre A. Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies. Blood Cancer J. 15(1), 210 (2025).","journal-title":"Blood Cancer J."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0148"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0014"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0063"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0212"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0189"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0071"},{"issue":"1","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"e12268","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard CH","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement. (N Y) 8(1), e12268 (2022).","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"12","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with Type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang W","year":"2024","unstructured":"Wang W, Wang Q, Qi X Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with Type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 20(12), 8661\u20138672 (2024).","journal-title":"Alzheimers Dement."},{"issue":"9","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamainternmed.2023.2067","article-title":"Detecting selection bias in observational studies \u2013 when interventions work too fast","volume":"183","author":"Mohyuddin GR","year":"2023","unstructured":"Mohyuddin GR, Prasad V. Detecting selection bias in observational studies \u2013 when interventions work too fast. JAMA Intern. Med. 183(9), 897\u2013898 (2023).","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i medications for Type 2 diabetes and Alzheimer disease and related dementias","volume":"82","author":"Tang H","year":"2025","unstructured":"Tang H, Donahoo WT, DeKosky ST GLP-1RA and SGLT2i medications for Type 2 diabetes and Alzheimer disease and related dementias. JAMA Neurol. 82(5), 439\u2013449 (2025).","journal-title":"JAMA Neurol."},{"issue":"9","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/ANNALS-24-02648","article-title":"Glucagon-like peptide-1 receptor agonists and incidence of dementia among older adults with Type 2 diabetes: a target trial emulation","volume":"178","author":"Inoue K","year":"2025","unstructured":"Inoue K, Saliba D, Gotanda H Glucagon-like peptide-1 receptor agonists and incidence of dementia among older adults with Type 2 diabetes: a target trial emulation. Ann. Intern. Med. 178(9), 1258\u20131267 (2025).","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_5_19_2","unstructured":"Novo Nordisk. News details. https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html"},{"key":"e_1_3_5_20_2","unstructured":"Alzheimer's Association. Alzheimer's Association Statement on oral semaglutide phase III topline data release. (2025). https:\/\/www.alz.org\/news\/2025\/alzheimers-association-statement-oral-semaglutide-phase-3-topline-data-release"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:19:31Z","timestamp":1781695171000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2026-0073"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0073","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e260073"}}